Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
Summary
This a Phase I/II randomized trial for patients with relapsed refractory Multiple Myeloma who have relapsed after treatment with prior therapies. The protocol is designed to evaluate two agents, Anti-LAG-3 and Anti-TIGIT, in order to understand their immunologic effects and safety both as single agents and in combination with pomalidomide and dexamethasone. In these arms, patients will be treated with either Anti-LAG-3 or Anti-TIGIT respectively for one cycle as single agent followed by the addition of pomalidomide and dexamethasone in combination for subsequent cycles. A third arm allows patients to be treated with the FDA approved combination of elotuzumab plus pomalidomide and dexamethsone as a control. This arm will thus allow a concurrent standard of care comparator for the experimental arms.
Timeline
- Start
- 2020-07-10
- Primary completion
- 2024-08-30
- Completion
- 2024-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Elotuzumab | Monoclonal antibody | — | — |
| Subject | RENVISTOBART | Monoclonal antibody | — | — |
| Subject | Relatlimab | Monoclonal antibody | — | — |
| Background | Dexamethasone | Small molecule | — | — |
| Background | Pomalidomide | Other / unclassified | — | — |